Nanotechnology Versus Cancer
With only one approved drug and many failures, the cancer vaccine field has lost some of its shine. Could nanotechnology brighten its prospects?
Ronak Savla |
We need a new type of weapon in the war on cancer. Chemotherapy, the backbone of cancer treatment, often brings initial success but cancers are notorious for relapsing in ever more aggressive and resistant forms. Traditional chemotherapies do not discriminate. They attack all rapidly dividing cells and are plagued by a narrow therapeutic index, numerous side effects, and high likelihood of resistance (1). Newer, molecularly targeted agents sidestep many of these problems, but often require lifelong treatment. And because these agents are relatively new, their long-term efficacy and safety are yet to be determined, and it is likely that we will see resistance develop over time.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE!
Or register now - it’s free!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine